Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Mental Health Issue, Depression/Anxiety,...
Phase NA
Enrollment 30
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The pilot study on the impact of a Psychiatric Consultation-Liaison Intervention in Primary Care Medical Consultations in French-speaking Switzerland (PLIMeC-P), is a mixed method randomized controlled trial. The investigated health-related intervention is a brief Consultation-Liaison (CL) psychiatry intervention in primary care. Primary Care Physicians (PCPs) have a key role in preventing, detecting, and managing mental disorders. Therefore, the optimization of both the quality of their interventions and their cooperation with psychiatric and psychological care networks are important challenges. It is well demonstrated that multidisciplinary interventions improve the efficacy of mental health care, CL psychiatry being one such type of intervention. Therefore, community CL-psychiatry, for example in private primary care group practices, are rare. The impact of such community, primary care CL-psychiatry interventions, should be investigated. The mixed methods randomized controlled trial PLIMeC study will examine the impact of a CL-psychiatric intervention in primary care settings, for newly reported mental illness, versus a Treatment As Usual (TAU) control arm. The intervention consists of a CL-psychiatric intervention into private medical practices, provided to patients suffering from mental health problems, a group of patients generally under-treated. The CL-psychiatrist will receive and discuss PCPs' referrals for patients with mental distress, who don't have a psychiatric follow-up. After a brief intervention (1-4 sessions), feedback conjoint (PCP-psychiatrist) session will be organized, to complete the intervention and provide proposals. The pilot study (PLIMeC-P) will determine whether the main planned study (PLIMeC) is feasible and practicable. It will be conducted on two sites, the Neuchâtel Psychiatry Centre (CNP) and the North-west Adult Psychiatry Service (SPANO), Department of Psychiatry of CHUV, Yverdon. For the pilot study (PLIMeC-P), 15 eligible participants are expected for each group, 30 participants in total. They will be recruited in three private primary care group practices. After eligibility and randomization 15 participants will be included for the intervention arm (brief CL-psychiatric intervention) and 15 for the control arm (TAU). The expected number of participants for the main trial (PLIMeC) will be estimated through analysis of the initial results of the PLIMeC-P.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Intervention arm - Consultation-Liaison (CL) brief psychiatric intervention in primary care settings — The CL brief psychiatric intervention (2 months) in the primary setting will consist of 3 different phases: 1. A direct referral of their PCP to the practice's CL psychiatrist will be held directly after the inclusion of the patient to the intervention arm, by conducting a clinical exchange (by oral or by mail) with the latter. 2. The CL psychiatrist will organize rapidly (in a delay of 1-2 weeks) a first session and will perform 1 to 4 psychiatric sessions, depending on the participant's needs. These sessions will take place in his/her consultation room, located in the referring PCP's practice, and will be completed in less than 2 months. No intervention guide will be provided to perform these sessions. 3. A joint feedback session between the PCP, the participant, and the CL psychiatrist will be organized (2 months after the first psychiatric session), during which the CL psychiatrist will make restitution of his/her proposals, from a biopsychosocial perspective.
  • Other: Control Arm - Treatment As Usual (TAU) — PCPs will explain to the participants that they will treat their psychological suffering, by providing the usual care for patients with psychiatric co-morbidities. Treatment as usual (TAU) by the PCP may involve supportive care (psychoeducation, psychotherapeutic support, social interventions, etc.), referral to a mental health provider (psychotherapist, psychiatrist, psychiatric nurse, etc.), treatment with psychotropic drugs, hypnosis, acupuncture, relaxation, etc. So as to facilitate their task, PCPs participating in this study will be provided with a list of mental health workers that they could contact.

Primary Outcomes

  • Evaluate the feasibility of the main PLIMeC study (Up to 20 months)
  • Mental health - psychiatric symptoms (After enrolment, one-year follow-up will be carried out for each participant. Measurements will be performed at baseline, 3, 6 and 12 months (T0, T1, T2 and T3) for the intervention and control groups.)
  • Mental health - Quality of life (After enrolment, one-year follow-up will be carried out for each participant. Measurements will be performed at baseline, 3, 6 and 12 months (T0, T1, T2 and T3) for the intervention and control groups.)
  • Mental health - Self-report questionnaire (After enrolment, one-year follow-up will be carried out for each participant. Measurements will be performed at baseline and 12 months (T0 and T3) for the intervention and control groups.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-01
Completion: 2025-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
Collaborators: Neuchâtel Psychiatry Centre (CNP), University of Lausanne Hospitals
Contact Information
Study Contact:
Konstantinos Tzartzas, MD
0041 21 314 61 10
konstantinos.tzartzas@unisante.ch
Stéphane Saillant, PD
0041 32 755 15 15
stephane.saillant@cnp.ch
Stéphane Saillant, PD
0041 32 755 15 15
stephane.saillant@cnp.ch
Centre Neuchâtelois de Psychiatrie (CNP)
Interventions
  • Other: Intervention arm - Consultation-Liaison (CL) brief psychiatric intervention in primary care settings — The CL brief psychiatric intervention (2 months) in the primary setting will consist of 3 different phases: 1. A direct referral of their PCP to the practice's CL psychiatrist will be held directly after the inclusion of the patient to the intervention arm, by conducting a clinical exchange (by oral or by mail) with the latter. 2. The CL psychiatrist will organize rapidly (in a delay of 1-2 weeks) a first session and will perform 1 to 4 psychiatric sessions, depending on the participant's needs. These sessions will take place in his/her consultation room, located in the referring PCP's practice, and will be completed in less than 2 months. No intervention guide will be provided to perform these sessions. 3. A joint feedback session between the PCP, the participant, and the CL psychiatrist will be organized (2 months after the first psychiatric session), during which the CL psychiatrist will make restitution of his/her proposals, from a biopsychosocial perspective.
  • Other: Control Arm - Treatment As Usual (TAU) — PCPs will explain to the participants that they will treat their psychological suffering, by providing the usual care for patients with psychiatric co-morbidities. Treatment as usual (TAU) by the PCP may involve supportive care (psychoeducation, psychotherapeutic support, social interventions, etc.), referral to a mental health provider (psychotherapist, psychiatrist, psychiatric nurse, etc.), treatment with psychotropic drugs, hypnosis, acupuncture, relaxation, etc. So as to facilitate their task, PCPs participating in this study will be provided with a list of mental health workers that they could contact.
Study Locations (3 sites)
Centre Neuchâtelois de Psychiatrie (CNP), Neuchâtel, Canton of Neuchâtel 2000 Switzerland
Center for Primary Care and Public Health (Unisanté) - Sponsorship / Not recruiting site, Lausanne, Canton of Vaud 1010 Switzerland
Service de psychiatrie de l'adulte nord ouest (SPANO) Département de psychiatrie - CHUV (DP-CHUV), Yverdon-les-Bains, Canton of Vaud 1400 Switzerland
Eligibility Criteria
Inclusion Criteria: * Aged more than 18 years * Signed informed consent to study protocol * Referred by their PCP due to mental distress, psychiatric symptoms, or complexity of medical care * Having fluent knowledge of the local language or being accompanied by an interpreter Exclusion Criteria: * Not being able to give an informed consent and follow the procedure of the study (due to dementia, restriction of intellectual capacity, acute confusional state, language problem) * Presenting an acute psychotic symptomatology, a hetero-aggression risk or an acute suicidality * Having an ongoing psychiatric follow-up
Conditions Pre-Eclampsia
Phase NA
Enrollment 224
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to compare the effects of aerobic (AE), resistance (RE), and combination (AERE) exercise throughout pregnancy on selected maternal and fetal/neonatal physiological variables in women at-risk for preeclampsia. The central hypothesis of this project is that exercise will decrease severity and occurrence of preeclampsia symptoms, thus improving maternal, pregnancy, and birth outcomes. Aim 1. Determine the influence of different exercise modes during pregnancy at risk of preeclampsia on maternal cardiometabolic health. Aim 2. Determine the most effective exercise mode in pregnancy at risk of preeclampsia on improving birth and infant health outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: Exercise Modes — Moderate intensity aerobic exercise Moderate intensity resistance exercise Moderate intensity combination exercise

Primary Outcomes

  • Systolic Blood Pressure (16wks) (16 weeks gestation)
  • Systolic Blood Pressure (20wks) (20 weeks gestation)
  • Systolic Blood Pressure (24wks) (24 weeks gestation)
  • Systolic Blood Pressure (28wks) (28 weeks gestation)
  • Systolic Blood Pressure (32wks) (32 weeks gestation)
  • Systolic Blood Pressure (36wks) (36 weeks gestation)
  • Maternal Cardiometabolic Risk (CMR) Score (during pregnancy)
  • Symptom Occurrence (at delivery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-24
Completion: 2027-12-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 224 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: East Carolina University
Principal Investigators:
  • Linda E May, MS, PhD (PRINCIPAL_INVESTIGATOR) - East Carolina University
Contact Information
Study Contact:
Linda E May, MS, PhD
2527377072
mayl@ecu.edu
James DeVente, MD
deventeja@ecu.edu
Linda E May, MS, PhD
2527377072
mayl@ecu.edu
East Carolina University
Interventions
  • Behavioral: Exercise Modes — Moderate intensity aerobic exercise Moderate intensity resistance exercise Moderate intensity combination exercise
Study Locations (1 sites)
East Carolina University, Greenville, North Carolina 27834 United States
Eligibility Criteria
Inclusion Criteria: * healthy women, age 18-40 years, \<16 weeks' gestation, with singleton pregnancy; women (BMI:18.5-45.0), sedentary, cleared by their obstetric provider. Exclusion Criteria: * pre-existing chronic conditions such as HIV, lupus, etc.; taking medicines that affect fetal development; and/or lack of telephone or email contact information).
Conditions Pulmonary Hypertension, Pulmonary Arteri...
Phase PHASE2
Enrollment 14
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: 129Xe Hyperpolarized — Each xenon dose will be limited to a volume less than 25% of participant lung capacity (TLC).

Primary Outcomes

  • Change in Xenon MRI Red Blood Cell (RBC) percentage (baseline, 3,and 12 months)
  • Change in cardiogenic oscillation amplitudes (baseline, 3, and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-10-27
Completion: 2030-02-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 14 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bastiaan Driehuys
Collaborators: Merck Sharp & Dohme LLC
Principal Investigators:
  • Sudarshan Rajagopal, MD, PhD (PRINCIPAL_INVESTIGATOR) - Duke University
Contact Information
Study Contact:
Claudia Salazar
+1 919 660 2026
claudia.salazar@duke.edu
Claudia Salazar, BS
919-660-2026
claudia.salazar@duke.edu
Duke University Medical Center
Sudarshan Rajagopal, MD, PhD
Duke University Medical Center
Interventions
  • Drug: 129Xe Hyperpolarized — Each xenon dose will be limited to a volume less than 25% of participant lung capacity (TLC).
Study Locations (1 sites)
Duke University Medical Center, Durham, North Carolina 27710 United States
Eligibility Criteria
Inclusion Criteria: 1. Outpatients of either gender, Age 18-75 2. Diagnosis of precapillary PH (right heart catheterization demonstrating hemodynamic criteria of a mean pulmonary artery pressure (mPAP) ≥ 20 mmHg, pulmonary vascular resistance ≥ 5 WU, pulmonary capillary wedge pressure ≤ 15 mmHg) in the setting of Group 1 (PAH) 3. Willing and giving informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed). 4. On a stable dose of background PAH therapy for \> 90 days prior to study enrollment 5. Women of childbearing potential must have a negative urine pregnancy test before MRI Exclusion Criteria: 1. Moderate to severe heart disease (LVEF \< 45%, Severe LV hypertrophy, Moderate to severe valvular disease) 2. Chronic thromboembolic disease 3. PH due to schistosomiasis 4. Active cancer 5. Sickle cell anemia 6. Prisoners and pregnant women will not be approached for the study 7. Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine) 8. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the participant or interfere with the participant's ability to comply with the protocol requirements
Conditions Breast Carcinoma, Colorectal Carcinoma, ...
Phase Not Applicable
Enrollment 2000
Locations 467 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Non-interventional Study — Non-interventional study

Primary Outcomes

  • Cancer-related symptoms (Baseline and re-assessed monthly up to 12 months post-enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-30
Completion: 2028-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wake Forest University Health Sciences
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Glenn Lesser, MD (STUDY_CHAIR) - Wake Forest University Health Sciences
Contact Information
Study Contact:
Karen Craver
336-716-0891
NCORP@wfusm.edu
907-458-3043
Veronica.Stevenson@foundationhealth.org
Fairbanks Memorial Hospital
Nicholas J DiBella
Fairbanks Memorial Hospital
Interventions
  • Other: Non-interventional Study — Non-interventional study
Study Locations (467 sites)
Fairbanks Memorial Hospital, Fairbanks, Alaska 99701 United States
Kingman Regional Medical Center, Kingman, Arizona 86401 United States
Cancer Center at Saint Joseph's, Phoenix, Arizona 85004 United States
Mercy Hospital Fort Smith, Fort Smith, Arkansas 72903 United States
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas 72401 United States
Kaiser Permanente-Deer Valley Medical Center, Antioch, California 94531 United States
Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California 93420 United States
PCR Oncology, Arroyo Grande, California 93420 United States
Mercy Cancer Center - Carmichael, Carmichael, California 95608 United States
Mercy San Juan Medical Center, Carmichael, California 95608 United States
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or older with one of the following newly diagnosed cancers: breast cancer, colorectal cancer, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer (e.g. adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous cell carcinoma, and not otherwise specified). * Planned treatment with systemic chemotherapy (single or multi-agent, includes targeted therapy) and/or immune checkpoint inhibitor therapy (targeting PD-1, PD-L1 or CTLA-4). If unable to engage participant before treatment starts, enrollment is allowed up to the start of Cycle 2 treatment. * Participants must be able to comprehend English or Spanish (for survey completion). * Participants must have a working email address and be must be willing to complete surveys online. This can be completed at home, in the clinic or other location. * Completion of the confidential Self-Reported Screening Survey and receipt of a screening result - eligible for enrollment. * Participant must reside in the United States, officially determined per patient report on Self-reported Screening Survey * In the treating provider's opinion, the participant should have a life expectancy of \>=6 months. Participants in hospice are not eligible. Optional Sub-study (available at select sites only): * Must be willing to participate in both the main study and the sub-study at the Wake Forest University Comprehensive Cancer Center (WF CCC) and Virginia Commonwealth University (VCU). * Must be receiving treatment at the WF CCC and VCU. * Must be diagnosed with non-small cell lung cancer. * Must be planning to receive paclitaxel as part of their chemotherapy in conjunction with Immune Checkpoint Inhibitor (ICIs) PD-1, PD-L1 or CTLA-4. Exclusion Criteria: * Currently enrolled in an interventional supportive treatment trial to manage cancer symptoms. * Participants with known pregnancy. * Participant received systemic therapy treatment for prior cancer(s) including chemotherapy, immunotherapy, targeted therapy, and hormonal therapy. * Participants enrolled in hospice. Optional Substudy (available at select sites only): * Participants with chronic or ongoing steroid or immunomodulatory agents (i.e., prednisone, dexamethasone, etanercept, infliximab, etc.). The use of glucocorticoids as pre-medications for chemotherapy treatment is allowed. * Participants with a history of HIV, hepatitis B or hepatitis C.
Conditions Major Depressive Disorder, Obsessive-Com...
Phase PHASE2
Enrollment 180
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Device: Transcranial magnetic stimulation — Accelerated TMS will be provided for 2 days using the same dosing regimen as the FDA-cleared SAINT protocol, ten 9-minute treatments per day.

Primary Outcomes

  • Clustering of multiple behavioral measures (through study completion, average of 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-01-30
Completion: 2030-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Brigham and Women's Hospital
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Shan H Siddiqi, MD (PRINCIPAL_INVESTIGATOR) - Brigham and Women&#39;s
Contact Information
Study Contact:
Emily Aquadro, MD
857-307-0294
expedition@mgb.org
Danielle DeSouza, PhD
857-307-0294
expedition@mgb.org
Acacia Clinics
Danielle DeSouza, MD
Acacia Clinics
Interventions
  • Device: Transcranial magnetic stimulation — Accelerated TMS will be provided for 2 days using the same dosing regimen as the FDA-cleared SAINT protocol, ten 9-minute treatments per day.
Study Locations (2 sites)
Acacia Clinics, Sunnyvale, California 94087 United States
Brigham and Women's Hospital, Boston, Massachusetts 02115 United States
Eligibility Criteria
Inclusion Criteria: * Age 18-65 * English proficiency sufficient for informed consent, questionnaires/tasks, and treatment * Primary diagnosis of one of the following: major depressive disorder (MDD), obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), or schizophrenia (determined by focal assessment using the Structured Clinical Interview for DSM-5) * ≥20 on the Beck Depression Inventory for patients with MDD * ≥16 on the Beck Anxiety Inventory for patients with GAD * ≥16 on the Yale-Brown Obsessive-Compulsive Scale for patients with OCD * ≥58 on the Positive and Negative Symptom Scale for patients with schizophrenia * Stable psychotropic medication regimen, or remain medication free, for 4 weeks prior to treatment (Medication changes during study enrollment period will be tracked for post hoc analysis). * Primary clinician (e.g. psychiatrist, therapist, psychologist, APRN, PA, etc.) responsible for psychiatric care before, during, and after the trial Exclusion Criteria: * Active pregnancy as determined by a urine pregnancy test * Cluster B personality disorders (antisocial personality disorder, borderline personality disorder, histrionic personality disorder, narcissistic personality disorder) * PTSD with active, clinically significant symptoms, as determined by clinician * Diagnosis of Schizoaffective Disorder, Bipolar Type * Recent (within 4 weeks) or concurrent use of rapid-acting antidepressant agent (ketamine/esketamine/ECT) * Ferromagnetic metallic implant that would contraindicate receiving TMS or obtaining MRI * Any other TMS or MRI safety concerns identified by the clinician * Receiving or planning to receive other TMS treatments during course of participation * History of: * Neurosurgical intervention for mental illness * Moderate to severe autism spectrum disorder * Intellectual disability * Severe cognitive impairment * Significant neurological illness (e.g., dementia, Parkinson's, Huntington's, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis) * Untreated or insufficiently treated endocrine disorder * Eating disorders * Treatment with investigational drug or intervention during the study period * Current evidence of: * Mania or hypomania * Active suicidal ideation or a suicide attempt within the past year * Contraindications to either TMS or MRI (e.g., metallic implants, etc.). * Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal * Significantly increased seizure risk as determined by a clinician * For participants with schizophrenia: * Evidence of impaired capacity to consent, e.g. impaired insight into illness, as deemed by a licensed psychiatrist or psychologist on the study team * Hospitalization with psychosis in the past 6 months * Positive urine drug screen for illicit substances * Existing tinnitus (ringing in the ears) * Any other condition deemed by the PI to interfere with the study or increase risk to the participant
Conditions Breast Cancer
Phase NA
Enrollment 264
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study compares the quality of sexual life of breast cancer patients under two types of oncoSexology supportive care : personalized supportive care versus on-request. The aim is to improve the quality of sexual life of these patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Quality of life questionnaire (QLQ) — Quality of life questionnaire : EORTC QLQ-C30, EORTC QLQ-Breast cancer module (BR) 23, EORTC SHQ-C22 et HADS at inclusion, visit 1 (6 months +/-1 month before the inclusion), visit 2 (12 months +/-1 month before the inclusion), visit 3 (18 months +/-1 month before the inclusion) and visit 4 (24 months +/-1 month before the inclusion).
  • Other: Satisfaction survey — The satisfaction score will be collected using a visual analog scale from 0 to 10 and the satisfaction questionnaire will also be completed at visit 4 (24 months +/- 1 month before the inclusion).
  • Other: Assessment of patient needs in the field of oncosexology — Assessment of patient needs in the field of oncosexology during a face-to-face or virtual interview at inclusion and every 6 months for 2 years. If a need is identified, an oncosexology consultation will be organised. Following this, a personalised care plan may be proposed.

Primary Outcomes

  • Comparison of the quality of sexual life of patients in the intervention arm and patients in the control arm (at 12 months after the inclusion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-09
Completion: 2028-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 264 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Principal Investigators:
  • Véronique D'HONDT, Dr (PRINCIPAL_INVESTIGATOR) - Institut du Cancer de Montpellier (ICM)
Contact Information
Study Contact:
Aurore MOUSSION
04 67 61 31 02
DRCI-icm105@icm.unicancer.fr
Emmanuelle TEXIER
04 67 61 31 02
DRCI-icm105@icm.unicancer.fr
Aliette DEZELLUS, Dr
02 40 67 99 00
aliette.dezellus@ico.unicancer.fr
Institut de Cancérologie de l'Ouest
Interventions
  • Other: Quality of life questionnaire (QLQ) — Quality of life questionnaire : EORTC QLQ-C30, EORTC QLQ-Breast cancer module (BR) 23, EORTC SHQ-C22 et HADS at inclusion, visit 1 (6 months +/-1 month before the inclusion), visit 2 (12 months +/-1 month before the inclusion), visit 3 (18 months +/-1 month before the inclusion) and visit 4 (24 months +/-1 month before the inclusion).
  • Other: Satisfaction survey — The satisfaction score will be collected using a visual analog scale from 0 to 10 and the satisfaction questionnaire will also be completed at visit 4 (24 months +/- 1 month before the inclusion).
  • Other: Assessment of patient needs in the field of oncosexology — Assessment of patient needs in the field of oncosexology during a face-to-face or virtual interview at inclusion and every 6 months for 2 years. If a need is identified, an oncosexology consultation will be organised. Following this, a personalised care plan may be proposed.
Study Locations (9 sites)
Institut de Cancérologie de l'Ouest, Saint-Herblain, Saint Herblain 44805 France
Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, Vandoeuvre LES Nancy 54519 France
Centre Léon Bérard, Lyon, 69008 France
ICM Val d'Aurelle, Montpellier, 34298 France
Centre Antoine Lacassagne, Nice, 06189 France
CHU de Nîmes, Nîmes, 30029 France
Institut Curie, Paris, 75005 France
IUCT - Oncopole, Toulouse, 31100 France
Institut Gustave Roussy, Villejuif, 94800 France
Eligibility Criteria
Inclusion Criteria: * Woman or man at least 18 years old * Diagnosis of infiltrating breast cancer regardless of the biological characteristics of the tumor * Standard treatment by surgery, radiotherapy and/or chemotherapy, completed a maximum of 3 months ago with the exception of post-neoadjuvant treatments (chemotherapy, poly(ADP-ribose) polymerase (PARP) inhibitor, immunotherapy, targeted treatment, ...) which must have been started less than 3 months previously * Patient with sufficient command of the French language to be able to answer the questionnaires * Patient having given informed, written and express consent. * Affiliation to the French Social Security System * Willingness and ability to comply with scheduled visits, treatment plan and other study procedures Exclusion Criteria: * Patient already taken cared of in oncosexology. The following are not criteria for non-inclusion (a previous single consultation without treatment, use of local vaginal treatments) * Metastatic disease * Patient under guardianship, curatorship or safeguard of justice

The Friendship Bench Plus Trial

NCT06384209
Recruiting
Conditions Major Depressive Disorder, Severe Depres...
Phase NA
Enrollment 296
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomised controlled trial is to enhance the Friendship Bench intervention with antidepressants in adults with moderate to severe depression. The main questions it aims to answer are: 1. Is the combination of the Friendship Bench with nurse-led antidepressants prescribing superior to the Friendship Bench alone? 2. What are the barriers and enablers for the prescription of antidepressants by nurses in primary care? Type of study: Randomized controlled superiority trial Participants will be randomly selected and allocated into the control arm or intervention arm. Participants in the control arm will receive six sessions of the Friendship Bench Problem Solving Therapy while those in the intervention arm will receive the Friendship Bench intervention plus Fluoxetine (Sertraline for breastfeeding women).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Fluoxetine — The treatment in the intervention arm consists of the Friendship Bench Plus Intervention (FB+) which combines six sessions of problem-solving therapy for depression delivered by trained Lay Health Workers and nurse-led prescription of antidepressants. The nurse will begin on the day of the first FB counselling session with 20mg Fluoxetine. The nurse will then dispense the antidepressants for two weeks.If patients show \<30% improvement in PHQ-9 as compared to baseline on the sixth study visit, Fluoxetine will be increased to 40mg, reassured and encouraged that the goals they set can be achieved. At the three months follow-up we will re-administer the PHQ-9 and again calculate treatment response defined as \< 50% improvement (primary outcome). Non-responders will be re-evaluated by the nurse to enforce adherence to the antidepressant medication and Fluoxetine will be increased by 20mg
  • Drug: Sertraline Pill — The treatment in the intervention arm consists of the Friendship Bench Plus Intervention (FB+) which combines six sessions of problem-solving therapy for depression delivered by trained Lay Health Workers and nurse-led prescription of antidepressants. The nurse will begin on the day of the first FB counselling session with 50mg Sertraline for all breastfeeding women instead of Fluoxetine. The nurse will then dispense the antidepressants for two weeks.If patients show \<30% improvement in PHQ-9 as compared to baseline on the sixth study visit, Sertraline will be increased to 100mg, reassured and encouraged that the goals they set can be achieved. At the three months follow-up we will re-administer the PHQ-9 and again calculate treatment response defined as \< 50% improvement (primary outcome). Non-responders will be re-evaluated by the nurse to enforce adherence to the antidepressant medication, and Sertraline will be increased by 50mg
  • Behavioral: Friendship Bench Intervention- Problem Solving Therapy — The Friendship Bench Problem-solving therapy is an evidence-based intervention for depression delivered by Lay Health Workers according to an established manual. Patients are encouraged to come up with a list of their problems, to select one problem they want to tackle, brainstorm for solutions, identify the best solution, and develop an action plan to implement it until the next session. Each session consists of four stages, namely kuvhura pfungwa (opening the mind), kusimudzira (uplifting), kusimbisa (strengthening) and kusimbisisa (re-strengthening). The LHW helps patients to recognize potentially dysfunctional problem-solving and develop a realistic plan for the successful resolution of the prioritized problem. Participants are reassured and encouraged that the goals they set can be achieved. The sessions will be delivered approximately one week apart

Primary Outcomes

  • Treatment response (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-26
Completion: 2028-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 296 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Bern
Collaborators: University of Zimbabwe, Swiss National Science Foundation
Principal Investigators:
  • Monika Mueller, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Bern
  • Dickson Chibanda, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Zimbabwe
Contact Information
Study Contact:
Rukudzo Mwamuka, MBCHB, MMED(Psychiatry)
+263777065549
ruemwamuka.tsungu@gmail.com
Monika Mueller, PhD
+41798443882
monika.mueller@unibe.ch
Rukudzo Mwamuka, Mbchb,MMed(Psychiatry)
+263777065549
ruemwamuka.tsungu@gmail.com
University of Zimbabwe
Interventions
  • Drug: Fluoxetine — The treatment in the intervention arm consists of the Friendship Bench Plus Intervention (FB+) which combines six sessions of problem-solving therapy for depression delivered by trained Lay Health Workers and nurse-led prescription of antidepressants. The nurse will begin on the day of the first FB counselling session with 20mg Fluoxetine. The nurse will then dispense the antidepressants for two weeks.If patients show \<30% improvement in PHQ-9 as compared to baseline on the sixth study visit, Fluoxetine will be increased to 40mg, reassured and encouraged that the goals they set can be achieved. At the three months follow-up we will re-administer the PHQ-9 and again calculate treatment response defined as \< 50% improvement (primary outcome). Non-responders will be re-evaluated by the nurse to enforce adherence to the antidepressant medication and Fluoxetine will be increased by 20mg
  • Drug: Sertraline Pill — The treatment in the intervention arm consists of the Friendship Bench Plus Intervention (FB+) which combines six sessions of problem-solving therapy for depression delivered by trained Lay Health Workers and nurse-led prescription of antidepressants. The nurse will begin on the day of the first FB counselling session with 50mg Sertraline for all breastfeeding women instead of Fluoxetine. The nurse will then dispense the antidepressants for two weeks.If patients show \<30% improvement in PHQ-9 as compared to baseline on the sixth study visit, Sertraline will be increased to 100mg, reassured and encouraged that the goals they set can be achieved. At the three months follow-up we will re-administer the PHQ-9 and again calculate treatment response defined as \< 50% improvement (primary outcome). Non-responders will be re-evaluated by the nurse to enforce adherence to the antidepressant medication, and Sertraline will be increased by 50mg
  • Behavioral: Friendship Bench Intervention- Problem Solving Therapy — The Friendship Bench Problem-solving therapy is an evidence-based intervention for depression delivered by Lay Health Workers according to an established manual. Patients are encouraged to come up with a list of their problems, to select one problem they want to tackle, brainstorm for solutions, identify the best solution, and develop an action plan to implement it until the next session. Each session consists of four stages, namely kuvhura pfungwa (opening the mind), kusimudzira (uplifting), kusimbisa (strengthening) and kusimbisisa (re-strengthening). The LHW helps patients to recognize potentially dysfunctional problem-solving and develop a realistic plan for the successful resolution of the prioritized problem. Participants are reassured and encouraged that the goals they set can be achieved. The sessions will be delivered approximately one week apart
Study Locations (1 sites)
University of Zimbabwe, Harare, Zimbabwe
Eligibility Criteria
Inclusion Criteria: * Adults ≥18 years * Moderate to severe depression defined as PHQ-9 ≥ 11 * Treatment naïve to the Friendship Bench intervention at the time of recruitment * Speaks English or Shona (local language) * Written informed consent Exclusion Criteria: * Mild depression defined as PHQ-9 \<11 * Psychotic symptoms (SSQ-14 probing question 5 positive and confirmation by study coordinator) * High risk of suicide according to P4 screener * Patient has received FB in the past 12 months * Patient is currently under treatment (counselling, antidepressants, followed up by a psychiatrist) * History of or presenting with end-stage AIDS * History of or presenting with kidney failure * History of or presenting with liver failure * History of or presenting with serious cardio-vascular disease (including previous heart attack, stroke or arrhythmias) * History of or presenting with cancer * Positive urine pregnancy test * Clear intention of pregnancy during the study period * Not willing to use effective contraception during study period * Unable to comprehend the nature of the study in either English or Shona (local language)
Conditions Diabetes Mellitus, Type 2, Insulin Resis...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary aim of this study is to evaluate if a single bout of AM vs PM resistance exercise has different effects on insulin sensitivity and sleep. A randomized cross-over trial be used to compare resistance exercise at two different times of the day. Each condition will take place in a laboratory setting. Each condition will consist of exercise, overnight sleep, and oral glucose tolerance tests the following day. The AM exercise will occur \~1.5 hours after habitual wake, and PM exercise will occur \~11 hours after habitual wake. After a 2-6 week washout, participants will complete the other condition. The hypothesis is that PM exercise will be more beneficial than AM exercise in improving insulin sensitivity. This study could identify if there is a better time of day to perform resistance exercise to decrease risk of developing Type 2 Diabetes Mellitus.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Resistance Exercise Timing — 1 resistance exercise session consisting of 3 sets, 10 repetitions per set, on 12 different exercises

Primary Outcomes

  • Insulin sensitivity (1 day)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-15
Completion: 2025-12-31
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Utah
Contact Information
Study Contact:
Tanya M Halliday, PhD
801-213-1364
tanya.halliday@utah.edu
Study Email Study Email
8014487897
trexstudy@utah.edu
Jason V Thomas, MS
jason.v.thomas@utah.edu
University of Utah HPER E Buildling
Interventions
  • Behavioral: Resistance Exercise Timing — 1 resistance exercise session consisting of 3 sets, 10 repetitions per set, on 12 different exercises
Study Locations (1 sites)
University of Utah HPER E Buildling, Salt Lake City, Utah 84112 United States
Eligibility Criteria
Inclusion Criteria: * Men and women, all ethnicities, aged 50-74 years * BMI ≥25 kg/m² and \<45 kg/m² * Weight stable (less than 5% change in the past 6 months) * Generally healthy individuals * Not meeting recommended activity guidelines for aerobic or resistance exercise Exclusion Criteria: * Uncontrolled cardiovascular, metabolic, renal, or pulmonary disease * Cancer treatment in the past 5 years * Untreated thyroid disease or other medical conditions affecting weight or energy metabolism * Current use of weight loss medication or other medications likely to impact energy balance * Bariatric surgery or extensive bowel resection in the past 2 years * Current or recent history (past 2 years) of eating disorder * Diagnosis of insomnia, sleep apnea, or other sleep and circadian disorders * Non-English speaking * HbA1c \>6.5%
Conditions Depression, Unipolar
Phase NA
Enrollment 246
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The United States Food and Drug Administration (FDA) approved intermittent theta-burst stimulation (iTBS) in 2018 as a form of repetitive transcranial magnetic stimulation (rTMS). Hospitals worldwide use it to treat major depressive disorder (MDD). It is safe, effective, even for depressed patients unable to respond to standard pharmacological treatment and is more efficient than standard rTMS. In accordance with the approved treatment protocol, patients experience considerable sensory discomfort at a stimulation intensity of 120% of their resting motor threshold (rMT). Antidepressant effects of iTBS are believed to be mediated by modulating prefrontal excitability. There is still a lack of evidence to support the choice of 120% rMT as the optimal stimulation intensity, and the presumed superiority of higher stimulation intensities over lower intensities has yet to be proven. This knowledge gap has clinical implications since more tolerated treatments may lead to greater adherence, resulting in improved outcomes. The current study proposes a randomized, triple-arm, controlled trial to compare the efficacy of iTBS at 75% (iTBS75) and 120% (iTBS120) rMT with sham iTBS (SiTBS). Based on the following considerations, SiTBS was selected to be compared with iTBS75 and iTBS120: SiTBS will reveal placebo antidepressant effects and serve as a control. iTBS75 is selected because iTBS at 80% aMT exhibits significant excitatory effects on the motor cortex and corresponds to approximately 70% rMT. There is however, a distance of about 12.7mm between the coil and the motor cortex, whereas 14.4mm separates the coil from the dorsolateral prefrontal cortex (DLPFC). Accordingly, a resting motor threshold of 70% at the motor cortex corresponds to a distance-adjusted rMT of 75% at the DLPFC. Lastly, iTBS120 is chosen as the standard stimulation intensity in current iTBS depression trials. It is our intention to investigate the potential antidepressant effects of iTBS treatment at a much lower stimulation intensity than the one currently employed by most centers in the United States and approved in these centers. Thus, our study can contribute to establishing a treatment regimen with increased adherence and lower withdrawal rates.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Device: intermittent theta-burst stimulation (iTBS) — iTBS treatment will be performed as comprising 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz). iTBS consists of 2-second trains with an inter-train-interval of 8 seconds. Repeat trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20) which equals the standard number of pulses in a daily iTBS treatment session, as approved by the FDA. The stimulation site over the left DLPFC will be determined using the international 10-20 system for EEG electrodes corresponding to the F3 location. 20 daily treatment sessions will be performed from Mondays to Fridays for four weeks for all included patients. Treatments will be performed at the brain stimulation laboratory at the Hong Kong Polytechnic University. Stimulation will be delivered using a MagPro X100 model (details about MagPro X100: magventure.com/en\_eur/products/magpro-x100/ ) and a Cool-B65 A/P Butterfly Coil is used in this study.

Primary Outcomes

  • Montgomery-Asberg depression rating scale (MADRS) (through study completion, an average of 1 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-08
Completion: 2026-10-26
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 246 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Hong Kong Polytechnic University
Collaborators: Health and Medical Research Fund
Principal Investigators:
  • Georg Kranz, PhD (PRINCIPAL_INVESTIGATOR) - The Hong Kong Polytechnic University
Contact Information
Study Contact:
Georg Kranz, PhD
27664838
georg.kranz@polyu.edu.hk
Georg Kranz, PhD
2766
georg.kranz@polyu.edu.hk
The Hong Kong Polytechnic University
Interventions
  • Device: intermittent theta-burst stimulation (iTBS) — iTBS treatment will be performed as comprising 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz). iTBS consists of 2-second trains with an inter-train-interval of 8 seconds. Repeat trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20) which equals the standard number of pulses in a daily iTBS treatment session, as approved by the FDA. The stimulation site over the left DLPFC will be determined using the international 10-20 system for EEG electrodes corresponding to the F3 location. 20 daily treatment sessions will be performed from Mondays to Fridays for four weeks for all included patients. Treatments will be performed at the brain stimulation laboratory at the Hong Kong Polytechnic University. Stimulation will be delivered using a MagPro X100 model (details about MagPro X100: magventure.com/en\_eur/products/magpro-x100/ ) and a Cool-B65 A/P Butterfly Coil is used in this study.
Study Locations (1 sites)
The Hong Kong Polytechnic University, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * are aged between 18 and 70; * have a MDD diagnosis, single or recurrent episode, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, fifth edition criteria and confirmed by means of the Mini-International Neuropsychiatric Interview (MINI); * have a score of at least 18 on the 17-item Hamilton Rating Scale for Depression (HDRS17) in their current episode; * have failed to have a clinically significant response to two or more standard antidepressant treatments during their current episode; * have received stable psychopharmacological treatment within 4 weeks prior to screening; and * have normal thyroid function, Complete Blood Count, electrolytes, and liver enzyme levels based on pre-study blood work. Exclusion Criteria: * have a history of substance abuse or dependence in the past 3 months; * have a concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump; * show active suicidal intent (MADRS item 10 score \>4); * are pregnant; * have a lifetime MINI diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms; * have a metal implant or any other common MRI and TMS exclusion criteria; * take antiepileptic drugs or benzodiazepines corresponding to a dose of \>1 mg lorazepam per day; * have had initiation or dose change of any psychotropic medication in the 4 weeks prior to screening or * have undergone TMS in the past.

Physical Activity Program for TRD

NCT06404320
Recruiting
Conditions Treatment-resistant Depression, Major De...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a pilot study examining the delivery of a remotely delivered, one-on-one, individualized physical activity (PA) program in adult participants with treatment-resistant depression (TRD).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: PA program - MoveU.HappyU — Participants will meet with their program trainer once a week virtually for 4 weeks to engage in 30 minutes of behavioral change coaching and 30 minutes of a structured PA program that is tailored to their needs and goals. The intensity of the PA sessions will be self-selected. PA sessions will involve a warmup, a conditioning component consisting of individualized aerobic or resistance exercises, and a cool down/stretch. Participants will also be instructed to independently engage in PA (outside of their session with the trainer) for 120 minutes at 50-65% of their maximum work capacity. This can be done by engaging in PA between 3-5 times per week.

Primary Outcomes

  • Feasibility (13 weeks)
  • Acceptability (13 weeks)
  • Acceptability (13 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-19
Completion: 2025-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Unity Health Toronto
Collaborators: University of Toronto
Contact Information
Study Contact:
Venkat Bhat
416-360-4000
venkat.bhat@utoronto.ca
Venkat Bhat
St. Michael's Hospital, Unity Health Toronto
Interventions
  • Behavioral: PA program - MoveU.HappyU — Participants will meet with their program trainer once a week virtually for 4 weeks to engage in 30 minutes of behavioral change coaching and 30 minutes of a structured PA program that is tailored to their needs and goals. The intensity of the PA sessions will be self-selected. PA sessions will involve a warmup, a conditioning component consisting of individualized aerobic or resistance exercises, and a cool down/stretch. Participants will also be instructed to independently engage in PA (outside of their session with the trainer) for 120 minutes at 50-65% of their maximum work capacity. This can be done by engaging in PA between 3-5 times per week.
Study Locations (1 sites)
St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario Canada
Eligibility Criteria
Inclusion Criteria: 1. Sedentary adults (engage in less than 60 minutes of moderate-to-vigorous PA per week) between the ages of 18 and 65 years, inclusive, capable of giving informed consent. 2. Participants meeting diagnostic criteria for major depressive disorder without psychotic symptoms according to the Diagnostic and Statistical Manual of Mental Disorders - 5th Ed. and currently experiencing a major depressive episode (MDE) as confirmed by the Mini International Neuropsychiatric Interview (MINI). 3. A Montgomery-Åsberg Depression Rating Scale total score of ≥ 7 at screening (mild-to-severe MDE). 4. Failure of at least two trials of antidepressant therapy of adequate dose and duration during the current episode as established by the Antidepressant Treatment History Form and self-report. 5. Receiving treatments congruent with Canadian Network for Mood and Anxiety Treatments guidelines with no changes to treatments one month before screening (28 days). Exclusion Criteria: 1. Current symptoms of mania, hypomania, mixed episodes, or psychosis. 2. Have received a diagnosis of alcohol or a substance use disorder within the past 3 months or as confirmed by the MINI. Other secondary psychiatric comorbidities (e.g., anxiety disorders, trauma-related disorders, etc.) will not be excluded. 3. Pregnant females. 4. Acute risk for a cardiovascular event (i.e., cardiovascular event in the past within the past 12 months). 5. Have any medical contraindications to exercise according to the Physical Activity Readiness Questionnaire. 6. Self-reported balance, gait, or locomotion difficulties that would preclude participation in a PA program. 7. Have any other condition that, in the opinion of the investigator(s), would adversely affect the subject's ability to complete the study or its measures. 8. Have exercise-induced asthma. 9. Taking medication that interferes with heart rate response to exercise, such as beta blockers. 10. Do not own a smartphone. 11. Do not have reliable access to the Internet. 12. Have previously received intravenous ketamine treatment in the last 2 months. Non-English-speaking individuals are excluded because the ability to communicate study information, answer questions accurately and completely about the study, and obtain consent are necessary.
Conditions Pulmonary Hypertension Due to Lung Disea...
Phase Not Applicable
Enrollment 900
Locations 71 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Prospective study assessments — Patients will complete prospective assessments at 6- and 12-month intervals for up to 5 years. There will be 1 check in at the first 3 months of enrollment. Follow up visits will include a ±45 day visit window. If an assessment is performed within 45 days of the visit window as part of the patient's standard of care, those values will be used in place of a prospective assessment.

Primary Outcomes

  • Baseline characteristics as described by demographics, medical history, ILD history, PH history, family history (comorbidities), and diagnostic right heart catheterization values. (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-23
Completion: 2030-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 900 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: United Therapeutics
Contact Information
Study Contact:
United Therapeutics Global Medical Information
919-485-8350
clinicaltrials@unither.com
Tejaswini Kulkarni, MD
205-934-3411
University of Alabama at Birmingham
Karim El-Kersh, MD
602-229-2200
Banner Health - University Medical Center Phoenix
Interventions
  • Other: Prospective study assessments — Patients will complete prospective assessments at 6- and 12-month intervals for up to 5 years. There will be 1 check in at the first 3 months of enrollment. Follow up visits will include a ±45 day visit window. If an assessment is performed within 45 days of the visit window as part of the patient's standard of care, those values will be used in place of a prospective assessment.
Study Locations (71 sites)
University of Alabama at Birmingham, Birmingham, Alabama 35294 United States
Banner Health - University Medical Center Phoenix, Phoenix, Arizona 85006 United States
Cedars-Sinai Medical Center, Los Angeles, California 90048 United States
UC Davis Health Medical Center, Sacramento, California 95817 United States
University of Colorado - Anschutz Medical Campus, Aurora, Colorado 80045 United States
National Jewish Health, Denver, Colorado 80206 United States
Pasquerilla Healthcare Center - Georgetown University, Washington D.C., District of Columbia 20007 United States
University of Florida, Gainesville, Florida 32610 United States
NCH Research Institute, Naples, Florida 34102 United States
Advent Health Medical Group Advanced Lung Disease, Orlando, Florida 32804 United States
Eligibility Criteria
Inclusion Criteria: 1. Adults aged 18 years or older 2. Diagnosis of fibrotic ILD based on high-resolution computed tomography imaging, including but not limited to: 1. Idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis 2. Autoimmune ILD 3. Chronic hypersensitivity pneumonitis 4. Nonspecific interstitial pneumonia 5. Occupational lung disease 6. Combined pulmonary fibrosis and emphysema with fibrosis greater than the extent of emphysema on lung imaging as determined by the Investigator 3. For patients to be eligible for Cohorts 1 to 3: RHC confirmed PH (mean pulmonary artery pressure \>20 mmHg, pulmonary artery wedge pressure ≤15 mmHg, pulmonary vascular resistance \>2 WU). 4. For patients to be eligible for Cohort 1, they must not be receiving inhaled treprostinil at Baseline. 5. For patients to be eligible for Cohort 2, they must have initiated Tyvaso/Tyvaso DPI at 1 of the following time points: 1. Baseline 2. ≤90 days prior to Baseline 6. For patients to be eligible for Cohort 3, they must be receiving Tyvaso/Tyvaso DPI at Baseline and for \>90 days prior to Baseline. 7. For patients to be eligible for Cohort 4: Prior RHC not meeting the definition of PH as described in Inclusion Criterion 3 but has a pulmonary artery wedge pressure ≤15 mmHg. 8. Co-enrollment in other observational or interventional studies is permitted. 9. Patient is willing and able to provide informed consent and complete surveys/questionnaires in English or Spanish. Exclusion Criteria: 1. Confirmed diagnosis of Group 1, 2, 4, or 5 PH a. In cases in which a patient has a diagnosis of PH-ILD along with a concomitant diagnosis of another PH group (eg, Group 1), enrollment may be permitted at the Investigator's discretion if, in their clinical judgment, PH-ILD is the predominant driver of the patient's PH. 2. Confirmed diagnosis of Group 3 PH associated with lung diseases and or hypoxia other than fibrotic ILD, as outlined in Inclusion Criterion 2. 3. Patients receiving inhaled treprostinil (Yutrepia™) at Baseline. Patients receiving other forms of PH therapy will be eligible for enrollment.
Conditions Breast Cancer, Breast Carcinoma in Situ,...
Phase Not Applicable
Enrollment 1200
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study aspires to provide outcomes on surgery, quality of life and time-to-event outcomes following the development and validation of a standardised surgical assessment tool in a shared decision-making framework for patients with pre-invasive or invasive breast cancer with breast conservation.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Primary Outcomes

  • Avoidance of mastectomy (3 months)
  • Re-excision rates (3 months)
  • Patient reported outcomes, European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30) (Baseline, postoperative (6, 12, 24 months))
  • Patient reported outcomes, BreastQ module for Satisfaction with Breasts (Baseline, postoperative (6, 12, 24 months))
  • Patient reported outcomes, BreastQ module for Physical Wellbeing: Chest (Baseline, postoperative (6, 12, 24 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-01-01
Completion: 2032-12-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 1200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Uppsala University
Collaborators: Uppsala University Hospital, Royal Marsden NHS Foundation Trust, University of Sydney, Campus Bio-Medico University
Principal Investigators:
  • Andreas Karakatsanis, MD, PhD (PRINCIPAL_INVESTIGATOR) - Uppsala University
Contact Information
Study Contact:
Andreas U Karakatsanis, MD, PhD
+46765864826
andreas.karakatsanis@uu.se
Andreas Karakatsanis
+46765864826
andreas.karakatsanis@uu.se
Uppsala University Hospital
Peter A Barry
Royal Marsden Hospital
Interventions
N/A
Study Locations (3 sites)
Westmead Breast Cancer Institute, Sydney, Australia
Uppsala University Hospital, Uppsala, 75185 Sweden
Royal Marsden Hospital, London, United Kingdom
Eligibility Criteria
Inclusion Criteria: 1. Female aged above 18 years. 2. Signed and dated written informed consent before the start of specific protocol procedures; oral consent for the participants of the quality control retrospective cohort study before accepting to partake a telephone interview. 3. Patients with invasive breast cancer (IBC) or ductal cancer in situ (DCIS) or unclear lesions mandating surgical excision or benign lesions amenable for surgical resection with BCS. 4. ECOG performance status 0-2. Exclusion Criteria 1. Life expectancy of less than 6 months 2. Non candidate for breast conservation 3. Inability to understand given information and give informed consent or undergo study procedures